NO930521L - Cd40cr reseptor og ligander for denne - Google Patents
Cd40cr reseptor og ligander for denneInfo
- Publication number
- NO930521L NO930521L NO93930521A NO930521A NO930521L NO 930521 L NO930521 L NO 930521L NO 93930521 A NO93930521 A NO 93930521A NO 930521 A NO930521 A NO 930521A NO 930521 L NO930521 L NO 930521L
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- cells
- inhibiting
- helper
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83579992A | 1992-02-14 | 1992-02-14 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO930521D0 NO930521D0 (no) | 1993-02-12 |
NO930521L true NO930521L (no) | 1993-08-16 |
NO316024B1 NO316024B1 (no) | 2003-12-01 |
Family
ID=25270498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19930521A NO316024B1 (no) | 1992-02-14 | 1993-02-12 | Fusjonsprotein og antistoff som spesifikt binder til CD40CR |
Country Status (16)
Country | Link |
---|---|
US (2) | US6376459B1 (no) |
EP (2) | EP0555880B1 (no) |
JP (2) | JP4148537B2 (no) |
KR (1) | KR100301146B1 (no) |
AT (1) | ATE273998T1 (no) |
AU (2) | AU3298893A (no) |
CA (1) | CA2089229C (no) |
DE (1) | DE69333591T2 (no) |
DK (1) | DK0555880T3 (no) |
ES (1) | ES2225820T3 (no) |
FI (1) | FI117508B (no) |
IL (1) | IL104684A0 (no) |
NO (1) | NO316024B1 (no) |
NZ (1) | NZ245898A (no) |
PT (1) | PT555880E (no) |
ZA (1) | ZA931013B (no) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
DK0897983T3 (da) * | 1991-10-25 | 2003-08-11 | Immunex Corp | Antistoffer mod CD40-L |
US5961974A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US7070777B1 (en) * | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
AU5098493A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
DE69418349T2 (de) * | 1993-09-02 | 1999-09-09 | Trustees Of Dartmouth College | Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet |
US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
ZA946765B (en) * | 1993-09-02 | 1996-02-15 | Dartmouth College | Methods of prolonged suppression of humoral immunity |
EP0721469B1 (en) * | 1993-09-02 | 2000-01-05 | Trustees of Dartmouth College | Anti-gp39 antibodies and uses therefor |
WO1995014487A1 (en) * | 1993-11-24 | 1995-06-01 | The Australian National University | Treatment of viral disease with cd40l peptide |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
ATE309267T1 (de) | 1994-04-28 | 2005-11-15 | Boehringer Ingelheim Pharma | Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
US5652224A (en) | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
US6372208B1 (en) | 1999-09-28 | 2002-04-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
AU2556195A (en) | 1995-03-13 | 1996-10-02 | Regents Of The University Of Michigan, The | CD40 binding compositions and methods of using same |
US7427492B1 (en) | 1995-06-05 | 2008-09-23 | Human Genome Sciences, Inc. | Polynucleotides encoding human tumor necrosis factor receptor-like2 |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
PT833847E (pt) * | 1995-06-22 | 2004-02-27 | Biogen Inc | Cristais de fragmentos de ligando cd40 e sua utilizacao |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
DK0892643T4 (da) * | 1996-03-20 | 2009-12-14 | Bristol Myers Squibb Co | Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved |
JP2000515507A (ja) * | 1996-07-08 | 2000-11-21 | ザ トラスティズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 平滑筋細胞が関連する疾患を処置するためのt―bam(cd40l)技術の治療適用 |
US6645494B1 (en) | 1997-06-20 | 2003-11-11 | Tanox Pharma B.V. | Anti-CD40L immunotoxins for the treatment of diseases |
CA2223225A1 (en) * | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
WO1999051258A1 (en) * | 1998-04-03 | 1999-10-14 | Trustees Of Dartmouth College | USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE |
IL130989A0 (en) | 1999-07-20 | 2001-01-28 | Compugen Ltd | Variants of alternative splicing |
WO2001079555A2 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
AU2002211366A1 (en) | 2000-10-02 | 2002-04-15 | Chiron Corporation | Human anti-cd40 antibodies |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
EP1485480A2 (en) * | 2002-02-22 | 2004-12-15 | Compugen Ltd. | Cd40 splice variants, method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof |
US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
JP2005535572A (ja) | 2002-04-12 | 2005-11-24 | メディミューン,インコーポレーテッド | 組換え抗インターロイキン−9抗体 |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
EA010650B1 (ru) | 2003-09-29 | 2008-10-30 | Уоррен Фармасьютикалз, Инк. | Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
EP1791563A4 (en) | 2004-07-26 | 2009-07-08 | Biogen Idec Inc | ANTI-CD154 ANTIBODIES |
US20060121042A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
HUE026303T2 (hu) * | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
US8697846B2 (en) * | 2007-08-15 | 2014-04-15 | Emory University | Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology |
DK2132228T3 (da) | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf |
CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
RS57087B1 (sr) | 2011-04-21 | 2018-06-29 | Bristol Myers Squibb Co | Polipeptidi antitela koji antagonizuju cd40 |
EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
CA3054758A1 (en) * | 2017-03-07 | 2018-09-13 | Universitat Basel | Mr1 restricted t cell receptors for cancer immunotherapy |
JP2020521745A (ja) | 2017-05-24 | 2020-07-27 | エイエルエス・セラピー・デベロップメント・インスティテュートALS Therapy Development Institute | 治療用抗cd40リガンド抗体 |
TW201900213A (zh) * | 2017-05-27 | 2019-01-01 | 美商免疫醫療公司 | 免疫球蛋白a陽性細胞的調節 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5247069A (en) * | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
DE3815472A1 (de) * | 1988-05-06 | 1989-11-16 | Centre Regional De Transfusion | Monoklonaler antikoerper und seine verwendung |
AU661854B2 (en) * | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
BR9714523A (pt) | 1997-01-10 | 2000-05-02 | Biogen Inc | Tratamento de nefrite de lúpus com compostos anti-cd40l |
AU5623398A (en) | 1997-03-07 | 1998-09-22 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
WO1999000143A1 (en) | 1997-06-27 | 1999-01-07 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
-
1993
- 1993-02-10 IL IL104684A patent/IL104684A0/xx not_active IP Right Cessation
- 1993-02-10 CA CA2089229A patent/CA2089229C/en not_active Expired - Fee Related
- 1993-02-11 FI FI930605A patent/FI117508B/fi not_active IP Right Cessation
- 1993-02-12 NO NO19930521A patent/NO316024B1/no not_active IP Right Cessation
- 1993-02-12 ES ES93102279T patent/ES2225820T3/es not_active Expired - Lifetime
- 1993-02-12 AT AT93102279T patent/ATE273998T1/de active
- 1993-02-12 NZ NZ245898A patent/NZ245898A/en not_active IP Right Cessation
- 1993-02-12 DK DK93102279T patent/DK0555880T3/da active
- 1993-02-12 PT PT93102279T patent/PT555880E/pt unknown
- 1993-02-12 EP EP93102279A patent/EP0555880B1/en not_active Revoked
- 1993-02-12 AU AU32988/93A patent/AU3298893A/en not_active Abandoned
- 1993-02-12 DE DE69333591T patent/DE69333591T2/de not_active Expired - Lifetime
- 1993-02-12 EP EP04012091A patent/EP1489099A3/en not_active Withdrawn
- 1993-02-12 ZA ZA931013A patent/ZA931013B/xx unknown
- 1993-02-13 KR KR1019930002045A patent/KR100301146B1/ko not_active IP Right Cessation
- 1993-02-15 JP JP02553093A patent/JP4148537B2/ja not_active Expired - Lifetime
- 1993-08-31 US US08/114,944 patent/US6376459B1/en not_active Expired - Lifetime
-
1996
- 1996-11-26 AU AU71980/96A patent/AU701306B2/en not_active Expired
-
2003
- 2003-10-16 JP JP2003356578A patent/JP3984944B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-10 US US11/127,046 patent/US7445781B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR930017919A (ko) | 1993-09-20 |
JP4148537B2 (ja) | 2008-09-10 |
FI117508B (fi) | 2006-11-15 |
AU7198096A (en) | 1997-02-06 |
EP0555880A3 (en) | 1994-05-11 |
KR100301146B1 (ko) | 2001-10-22 |
ES2225820T3 (es) | 2005-03-16 |
IL104684A0 (en) | 1993-06-10 |
EP1489099A3 (en) | 2008-02-20 |
JP3984944B2 (ja) | 2007-10-03 |
CA2089229A1 (en) | 1993-08-15 |
JPH06220096A (ja) | 1994-08-09 |
ZA931013B (en) | 1993-09-20 |
DE69333591T2 (de) | 2005-09-01 |
EP0555880B1 (en) | 2004-08-18 |
US6376459B1 (en) | 2002-04-23 |
EP0555880A2 (en) | 1993-08-18 |
PT555880E (pt) | 2004-12-31 |
US7445781B2 (en) | 2008-11-04 |
MX9300768A (es) | 1997-09-30 |
DE69333591D1 (de) | 2004-09-23 |
FI930605A (fi) | 1993-08-15 |
AU3298893A (en) | 1993-08-19 |
US20060008460A1 (en) | 2006-01-12 |
JP2004115527A (ja) | 2004-04-15 |
NO316024B1 (no) | 2003-12-01 |
AU701306B2 (en) | 1999-01-28 |
DK0555880T3 (da) | 2004-12-06 |
EP1489099A2 (en) | 2004-12-22 |
NZ245898A (en) | 1995-04-27 |
NO930521D0 (no) | 1993-02-12 |
ATE273998T1 (de) | 2004-09-15 |
FI930605A0 (fi) | 1993-02-11 |
CA2089229C (en) | 2010-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO930521D0 (no) | Cd40cr reseptor og ligander for denne | |
AU706473B2 (en) | Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon | |
US20090136511A1 (en) | Interleukin-15 Antagonist Peptide | |
DE69840383D1 (de) | Ctl epitope des epstein-barr virus | |
Papadopoulos et al. | Oligoclonal immunoglobulins in patients with the acquired immunodeficiency syndrome | |
NO20002413D0 (no) | Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer | |
MXPA02011163A (es) | Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central. | |
ATE112783T1 (de) | Stressprotein aus bakterien. | |
EP0485471B1 (en) | Natural human anti-gamma interferon antibodies detected and purified by synthetic peptides | |
CA2157900A1 (en) | Therapeutic strategies for immunoinfective cluster virus infections | |
DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
ATE133708T1 (de) | Immunogenisches peptid von echinococcus granulosis, dafür kodierende dns sowie diagnostische und therapeutische verwendungen | |
US6294174B1 (en) | Peptides immunologically related to known viral protein | |
Fleischer | Superantigens | |
Rischmueller et al. | Human autoantibodies directed against the RNA recognition motif of La (SS‐B) bind to a conformational epitope present on the intact La (SS‐B)/Ro (SS‐A) ribonucleoprotein particle | |
CA2109961A1 (en) | Peptides for use in induction of t cell activation against hiv-1 | |
Chen et al. | Human autoantibody secreted by immortalized lymphocyte cell line against the 68K polypeptide of the U1 small nuclear ribonucleoprotein | |
Moran et al. | A novel technique for the production of hybrid antibodies | |
Lenert et al. | Human CD4-reactive antibodies from SLE patients induce reversible inhibition of polyclonal T lymphocyte proliferation | |
CA2107329A1 (en) | Anti-Human Immunodeficiency Virus Recombinant Antibodies | |
ES2278022T3 (es) | Anticuerpos naturales activos contra el virus vih. | |
Vaughan | Infection and autoimmunity | |
DK0470989T3 (da) | Anvendelse af monoklonale anti-beta2 mikroglobulin antistoffer | |
Hudecz et al. | New Branched Polypeptide Based Epitope-Conjugates: Synthesis and Immunrecognition | |
WO2001023428A3 (en) | Interleukin-2 receptor associated polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |